225 related articles for article (PubMed ID: 33995649)
1. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
2. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
[TBL] [Abstract][Full Text] [Related]
3. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
4. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract][Full Text] [Related]
7. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
[TBL] [Abstract][Full Text] [Related]
9. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
11. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Characterization of
Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
[TBL] [Abstract][Full Text] [Related]
15. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
Kerr CP; Grudzinski JJ; Nguyen TP; Hernandez R; Weichert JP; Morris ZS
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678756
[TBL] [Abstract][Full Text] [Related]
16. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
[TBL] [Abstract][Full Text] [Related]
17.
Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
Commun Biol; 2019; 2():79. PubMed ID: 30820474
[TBL] [Abstract][Full Text] [Related]
18.
Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
Front Immunol; 2020; 11():1610. PubMed ID: 32849544
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
20. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]